Medicina y Especialidades Médicas
Departamento
National Cancer Center Hospital
Kashiwa, Japón
Publicaciones en colaboración con investigadores/as de National Cancer Center Hospital (3)
2025
- Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Blood Advances, Vol. 9, Núm. 16, pp. 4248-4259
- CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC
JTO Clinical and Research Reports, Vol. 6, Núm. 8
- Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC
JTO Clinical and Research Reports, Vol. 6, Núm. 7
